30087289|t|Perinatal Hypoxic-Ischemic Encephalopathy and Neuroprotective Peptide Therapies: A Case for Cationic Arginine-Rich Peptides (CARPs).
30087289|a|Perinatal hypoxic-ischemic encephalopathy (HIE) is the leading cause of mortality and morbidity in neonates, with survivors suffering significant neurological sequelae including cerebral palsy, epilepsy, intellectual disability and autism spectrum disorders. While hypothermia is used clinically to reduce neurological injury following HIE, it is only used for term infants (>36 weeks gestation) in tertiary hospitals and improves outcomes in only 30% of patients. For these reasons, a more effective and easily administrable pharmacological therapeutic agent, that can be used in combination with hypothermia or alone when hypothermia cannot be applied, is urgently needed to treat pre-term (<=36 weeks gestation) and term infants suffering HIE. Several recent studies have demonstrated that cationic arginine-rich peptides (CARPs), which include many cell-penetrating peptides [CPPs; e.g., transactivator of transcription (TAT) and poly-arginine-9 (R9; 9-mer of arginine)], possess intrinsic neuroprotective properties. For example, we have demonstrated that poly-arginine-18 (R18; 18-mer of arginine) and its D-enantiomer (R18D) are neuroprotective in vitro following neuronal excitotoxicity, and in vivo following perinatal hypoxia-ischemia (HI). In this paper, we review studies that have used CARPs and other peptides, including putative neuroprotective peptides fused to TAT, in animal models of perinatal HIE. We critically evaluate the evidence that supports our hypothesis that CARP neuroprotection is mediated by peptide arginine content and positive charge and that CARPs represent a novel potential therapeutic for HIE.
30087289	10	41	Hypoxic-Ischemic Encephalopathy	Disease	MESH:D020925
30087289	62	69	Peptide	Chemical	MESH:D010455
30087289	92	123	Cationic Arginine-Rich Peptides	Chemical	-
30087289	125	130	CARPs	Chemical	-
30087289	143	174	hypoxic-ischemic encephalopathy	Disease	MESH:D020925
30087289	176	179	HIE	Disease	MESH:D020925
30087289	279	300	neurological sequelae	Disease	MESH:D009422
30087289	311	325	cerebral palsy	Disease	MESH:D002547
30087289	327	335	epilepsy	Disease	MESH:D004827
30087289	337	360	intellectual disability	Disease	MESH:D008607
30087289	365	390	autism spectrum disorders	Disease	MESH:D000067877
30087289	398	409	hypothermia	Disease	MESH:D007035
30087289	439	458	neurological injury	Disease	MESH:D020196
30087289	469	472	HIE	Disease	MESH:D020925
30087289	499	506	infants	Species	9606
30087289	588	596	patients	Species	9606
30087289	731	742	hypothermia	Disease	MESH:D007035
30087289	757	768	hypothermia	Disease	MESH:D007035
30087289	857	864	infants	Species	9606
30087289	875	878	HIE	Disease	MESH:D020925
30087289	926	957	cationic arginine-rich peptides	Chemical	-
30087289	959	964	CARPs	Chemical	-
30087289	990	1011	-penetrating peptides	Chemical	-
30087289	1013	1017	CPPs	Chemical	MESH:C014896
30087289	1067	1082	poly-arginine-9	Chemical	-
30087289	1194	1210	poly-arginine-18	Chemical	-
30087289	1212	1215	R18	ProteinMutation	tmVar:p|Allele|R|18;VariantGroup:0
30087289	1259	1263	R18D	ProteinMutation	tmVar:p|SUB|R|18|D;HGVS:p.R18D;VariantGroup:0
30087289	1304	1327	neuronal excitotoxicity	Disease	MESH:D009410
30087289	1361	1377	hypoxia-ischemia	Disease	MESH:D020925
30087289	1379	1381	HI	Disease	MESH:D020925
30087289	1432	1437	CARPs	Chemical	-
30087289	1448	1456	peptides	Chemical	MESH:D010455
30087289	1493	1501	peptides	Chemical	MESH:D010455
30087289	1546	1549	HIE	Disease	MESH:D020925
30087289	1657	1664	peptide	Chemical	MESH:D010455
30087289	1711	1716	CARPs	Chemical	-
30087289	1761	1764	HIE	Disease	MESH:D020925
30087289	Negative_Correlation	MESH:D009410	HGVS:p.R18D
30087289	Negative_Correlation	MESH:D009410	VariantGroup:0;tmVar:p
30087289	Association	MESH:D020925	HGVS:p.R18D
30087289	Association	MESH:D020925	VariantGroup:0;tmVar:p
30087289	Negative_Correlation	MESH:D010455	MESH:D020925

